uniQure Faces FDA Hurdles for Huntington’s Therapy as Cash Runway Extends
Event summary
- uniQure reported $622.5M in cash as of December 31, 2025, enough to fund operations into mid-2029.
- FDA rejected uniQure’s Phase I/II data for AMT-130, demanding a sham-controlled study for Huntington’s disease approval.
- AMT-260 epilepsy trial completed first cohort enrollment; additional data expected in Q2 2026.
- AMT-191 Fabry disease therapy showed durable enzyme activity increases but paused dosing due to liver enzyme elevations.
The big picture
uniQure’s strategic challenge lies in navigating FDA skepticism around gene therapy approvals while maintaining financial discipline. The biotech sector is increasingly scrutinizing the balance between innovative therapies and regulatory hurdles, particularly for rare diseases like Huntington’s. With a robust cash position, uniQure has breathing room but must demonstrate clinical efficacy to justify its valuation.
What we're watching
- Regulatory Pathway Uncertainty
- Whether uniQure can negotiate a viable Phase III study design with the FDA after its Type B meeting in Q2 2026.
- Cash Burn Management
- The pace at which uniQure’s $622.5M cash position will be depleted amid ongoing clinical trials and potential commercialization efforts.
- Pipeline Progress
- How AMT-191’s liver enzyme findings may impact its development timeline for Fabry disease treatment.
Related topics